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Abstract:  
Background & Aims: Pancreatitis is the most important risk factor for pancreatic 
ductal adenocarcinoma (PDAC). Pancreatitis predisposes to PDAC because it induces 
a process of acinar cell reprogramming known as acinar-to-duct metaplasia (ADM)—
a precursor of pancreatic intra-epithelial neoplasia lesions that can progress to PDAC. 
Mutations in KRAS are found at the earliest stages of pancreatic tumorigenesis, and it 
appears to be a gatekeeper to cancer progression. We investigated how mutations in 
KRAS cooperate with pancreatitis to promote pancreatic cancer progression in mice.  
 
Methods: We generated mice carrying conditional alleles of Yap1 and Taz and 
disrupted Yap1 and Taz using a Cre-lox recombination strategy in adult mouse 
pancreatic acinar cells (Yap1fl/fl;Tazfl/fl;Ela1-CreERT2). We crossed these mice 
with LSL-KrasG12D mice, which express a constitutively active form of KRAS after 
Cre recombination. Pancreatic tumor initiation and progression were analyzed after 
chemically induced pancreatitis. We analyzed pancreatic tissues from patients with 
pancreatitis or PDAC by immunohistochemistry. 
 
Results: Oncogenic activation of KRAS in normal, untransformed acinar cells in the 
pancreatic tissues of mice resulted in increased levels of pancreatitis-induced ADM. 
Expression of the constitutive active form of KRAS in this system led to activation of 
the transcriptional regulators YAP1 and TAZ; their function was required for 
pancreatitis-induced ADM in mice. The JAK–STAT3 pathway was a downstream 
effector of KRAS signaling via YAP1 and TAZ. YAP1 and TAZ directly mediated 
transcriptional activation of several genes in the JAK–STAT3 signaling pathway; this 
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could be a mechanism by which acinar cells that express activated KRAS become 
susceptible to inflammation. 
 
Conclusion: We identified a mechanism by which oncogenic KRAS facilitates ADM 
and thereby generates the cells that initiate neoplastic progression. This process 
involves activation of YAP1 and TAZ in acinar cells, which upregulate JAK–STAT3 
signaling to promote development of PDAC in mice.  
 
KEY WORDS: PanINs, pancreatic cancer progression, mouse model, inflammation 
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Introduction  
The most common and lethal tumor of the pancreas, pancreatic ductal 
adenocarcinoma (PDAC), exhibits the histological morphology and marker 
expression of pancreatic duct cells. However, many of these tumors originate from the 
other major exocrine cell type, acinar cells, through a reprogramming process known 
as acinar-to-ductal metaplasia (ADM)1. ADM is characterized by a change in marker 
expression: acinar cells positive for amylase also begin to express the ductal cell 
marker CK19. These poorly-differentiated cells express the pancreatic progenitor cell 
markers Pdx1 and Nestin2, 3 and are important precursors of malignancy4. Pancreatic 
intraepithelial neoplasia (PanIN) lesions have a well-established histological 
progression towards PDAC5, and can arise from ADM lesions1. Thus ADM is the 
earliest pre-neoplastic lesion that predisposes to PDAC, making acinar-to-duct 
reprogramming a crucial step in pancreatic cancer initiation. 
KRas mutations are found in more than 90% of all PDAC cases6 and they occur early, 
in low-grade pre-neoplastic lesions7, 8. Although the importance of KRas mutation in 
the development of ADM, PanIN and pancreatic tumors is well established9, the 
mechanisms by which oncogenic Ras leads to PDAC are not fully understood. 
Pancreatitis is a well-known risk factor for PDAC development in humans. Patients 
with hereditary pancreatitis show a 50-fold increase in pancreatic cancer incidence10. 
In mouse models, both acute and chronic inflammation of the pancreas accelerate 
pancreatic cancer progression1, 11. Pancreatitis can be induced experimentally by 
injection of caerulein, which induces acinar cell death and inflammation12. In 
caerulein-induced pancreatitis, inflammation induces acinar cells to reprogram to 
form ADM lesions11, which may be transient, or in the presence of a KRasG12D 
mutation, persistent13. TGFα administration or overexpression also cooperates with 
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KRasG12D to induce ADM in vitro3, 14. Thus, pancreatic inflammation facilitates 
tumorigenesis by inducing ADM.  
Expression of oncogenic KRasG12D at endogenous levels in acinar cells triggers 
progression to pancreatic adenocarcinoma very inefficiently. Stronger transgenic 
expression of oncogenic Ras15, or additional oncogenic stimuli, such as mutant p5316 
or TGFα overexpression17 are required. Many of these additional stimuli directly or 
indirectly increase Ras activity, suggesting that a positive feedback loop amplifying 
oncogenic Ras signaling is required for PDAC progression18. 
The reliance of established PDAC tumors on KRasG12D expression can be alleviated 
by upregulation of the transcriptional regulator YAP119. YAP1 has also been 
implicated in progression from PanIN to PDAC20, but its contribution at the 
reprogramming stage is unclear.  
Here we show that KRas mutation sensitizes acinar cells to reprogramming by 
activating YAP1 and TAZ signaling, which in turn upregulates components of the 
JAK-STAT3 pathway. This increases sensitivity to inflammatory stimuli, which 
induces widespread ADM among KRas-mutant acinar cells. Importantly, inhibiting 
KRasG12D- and pancreatitis-induced reprogramming by inactivating YAP1/TAZ also 
prevents progression to PanIN, underlining the importance of this mechanism for 
pancreatic cancer initiation. 
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Materials and Methods 
 
Mouse Lines 
For the generation of conditional Yap1 and Taz/Wwtr1 knock-out mice, ES cell clones 
carrying the respective targeted alleles were obtained from the Knockout Mouse 
Project (KOMP) Repository (Yap1<tm1a(KOMP)Mbp>; ES clone E08) and the 
European Conditional Mouse Mutagenesis (EUCOMM) Program 
(Wwtr1<tm1a(EUCOMM)Wtsi>; ES clone A08). Targeted ES cell clones (agouti 
C57BL/6 parental cell line JM8A3.N1) were injected into blastocysts of C57BL/6 
background to generate chimeric mice, which were then crossed with Flpo-expressing 
mice (Tg(CAG-Flpo)1Afst; C57BL/6 background)21 to remove the neo-selection 
cassette and obtain mice carrying the conditional floxed alleles 
Yap1<tm1c(KOMP)Mbp> and Wwtr1<tm1c(EUCOMM)Wtsi> isogenic on 
C57BL/6. The Flpo-allele was bred out and mice were maintained on a C57BL/6 
background. For genotyping and validation of knockout alleles, see Supplementary 
Figure 4 and Supplementary Materials and Methods. 
The Stat3fl/fl, Pdx1-Cre, R26-LSL-YFP, LSL-KRasG12D and Ela1-CreERT2 mouse lines 
have been described (see Supplementary Materials and Methods).  
 
Acute pancreatitis induction 
Acute pancreatitis in C57BL/6 mice was induced by eight intra-peritoneal injections 
of caerulein (Sigma-Aldrich) dissolved in PBS given at one-hour intervals on two 
consecutive days at a dose of 50 µg/kg body weight per injection (high dose). Other 
strains received a similar treatment schedule except with six injections at a dose of 40 
µg/kg body weight per injection (low dose). Control animals received injections of 
PBS only.  
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Gene set enrichment analysis 
Gene set enrichment analysis was performed on the published transcription profile of 
C57BL/6 Jackson mice treated with caerulein or PBS22 and on the transcription 
profile of mouse liver organoids overexpressing YAP123, with the software developed 
by the Broad Institute of MIT and Harvard. The settings are listed in Supplementary 
Materials and Methods.  
 
Primary acinar cell culture 
Mice were sacrificed by cervical dislocation, the pancreas was dissected out and 
transferred to ice-cold Hank’s balanced salt solution (HBSS) supplemented with 
Penicillin/Streptomycin (Sigma-Aldrich). Pancreata were cut into small pieces and 
digested with 2 mg/ml Collagenase P (Roche Diagnostics) in HBSS for 15 min at 37 
ºC. Cells were washed three times with HBSS supplemented with 5 % FBS and then 
filtered through 500 µm and 105 µm nylon meshes (Spectrum Laboratories). The cell 
suspension was layered on top of 30 % FBS in HBSS, centrifuged at 1000 r.p.m for 2 
min and the cell pellet was resuspended in acinar cell culture medium (Waymouth’s 
medium (Life Technologies) supplemented with 1 % FBS, Penicillin/Streptomycin 
(Sigma-Aldrich), 1 µg/ml Dexamethasone (Sigma-Aldrich) and 100 µg/ml Soybean 
trypsin inhibitor (Sigma-Aldrich)). The cell suspension was then infected with 
adenoviruses either obtained from the University of Iowa Carver College of Medicine 
(Ad5-GFP and Ad5-Cre-GFP), at a concentration of 1.25x107 plaque forming units 
(pfu)/ml, or generated by cloning (Ad-GFP, Ad-GFP-YAP1-5SA and Ad-GFP-TAZ-
S89A), at a concentration of 5x105 pfu/ml. Acinar cells were incubated with 
adenoviruses for 1 h at 37 ºC. 6-well tissue culture plates were coated with an 800 µl 
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layer of collagen solution (4 mg/ml rat tail collagen (BD Biosciences), 10 % 10x 
Waymouth’s medium (Sigma-Aldrich) and 0.02 mol/l NaOH (Sigma-Aldrich)). The 
cell suspension was mixed 1:1 with collagen solution and plated onto the collagen 
layer. The acinar cell/collagen mix was allowed to solidify for 1 h at 37 ºC before 
adding medium. Medium was changed on day 1 and day 3 after the isolation. 
Quantifications were done on day 5 after isolation. To harvest the cells, the collagen 
matrix was digested with 1 mg/ml collagenase P (Roche Diagnostics) diluted in 
HBSS for 30 min at 37 ºC.  
 
Production of recombinant adenoviruses 
The vectors harboring the coding sequences of the phosphorylation mutants of YAP1 
(5SA) and TAZ (S89A), kindly provided by S. Piccolo, were used to subclone the 
YAP1 and TAZ cDNAs in the pAd-Track-CMV vector (Addgene #16405). This 
results in the expression of YAP1/TAZ under the control of the CMV promoter and 
pAd-Track-CMV empty vector was used as control. The pAd-Track-CMV contains a 
GFP cDNA under control of a second CMV promoter. Recombinant adenoviruses 
expressing GFP, YAP1-5SA in combination with GFP or TAZ-S89A in combination 
with GFP were generated following the protocol as described24. Briefly, human 
HEK293A cells were co-transfected with pAd-Easy-1 (Addgene #16400) together 
with pAd-Track-CMV, pAd-Track-CMV-YAP1-5SA or pAd-Track-CMV-TAZ-
S89A. Adenoviruses were harvested 14 days after transfection. To generate higher 
viral titer, fresh HEK293A were infected with the adenoviruses and grown for 7 days 
before harvesting and this process was repeated three times. Adenoviruses were 
purified using the Adeno-X Maxi Purification Kit (TaKaRa Clontech) according to 
the manufacturer’s protocol. Virus titers were determined by infecting HEK293T cells 
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with a dilution series of the adenoviruses. After infection, cells were overlaid with 
agarose and plaques were visualized by MTT (Sigma-Aldrich) and quantified 7 days 
later. This protocol generated virus titer ranging from 1 to 6x108 pfu/ml. 
 
Immunoblot Analysis and Ras-GTP pulldown assay 
Protein lysates were obtained from dissected pancreata, primary acinar cells or 
PANC1 cells and homogenized in Cell Lysis Buffer (Cell Signaling) containing 
proteasome inhibitor (Sigma-Aldrich). Immunoblots were performed as described25. 
PVDF membranes (GE Healthcare) were incubated with antibodies against YAP1 
(Cell Signaling; #4912 and Santa Cruz; sc-15407), p-YAP1 (Ser127 in humans and 
Ser112 in mice; Cell Signaling; #4911); TAZ (Sigma-Aldrich; HPA007415), CK19 
(DHSB; TROMA-III), STAT3 (Cell Signaling; #4904), p-STAT3 (Tyr705; Cell 
Signaling; #9131); LATS1 (Cell Signaling; #3477), p-LATS1 (Ser909; Cell 
Signaling; #9157), LIFR (Santa Cruz; sc-659), PDX1 (R&D Systems, MAB2419), 
SOX9 (Millipore, AB5535), p-Erk1/2 (Thr202/Tyr204; Cell Signaling; #9106), 
Erk1/2 (Cell Signaling, #9102), GAPDH (Abcam; ab9485) and ACTIN (Abcam; 
ab49900). Active Ras levels were determined by Ras-GTP pulldown assay 
(ThermoFisher Scientific) using the Raf Ras-binding-domain fused to GST (Raf-
RBD-GST) according to the manufacturer’s instructions. Signal intensities of bands 
were quantified using ImageJ software. 
 
Statistics 
Statistical analysis was performed using GraphPad Prism 6.0a software and 2-tailed 
Student’s t-tests were used to generate P values. Normalized enrichment scores and 
nominal P values for the gene set enrichment analysis were generated using the 
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software developed by the Broad Institute of MIT and Harvard. P values less than 
0.05 were considered significant.  
 
Study Approval 
Mouse experiments were carried out with the approval of the London Research 
Institute’s Ethical Review Committee according to the UK Animals (Scientific 
Procedures) Act 1986. 
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Results 
YAP1 and TAZ are upregulated in pancreatitis 
ADM caused by pancreatitis is an initiating step in pancreatic tumor development1. 
To find molecular regulators of this process, we performed gene set enrichment 
analysis26 on the published transcriptional profile of mouse pancreata treated with 
caerulein22 to identify pathways upregulated in pancreatitis (Supplementary Figure 
1A). Many of these pathways, such as Wnt, Notch and JAK-STAT3, have previously 
been implicated in either acinar cell regeneration or in inducing ADM upon injury13, 
27-29
. Intriguingly, the highest gene set enrichment scores were for YAP1 target genes 
(Figure 1A and Supplementary Figure 1A). 
To investigate a possible role for YAP1/TAZ signaling in pancreatitis-induced ADM, 
we treated C57BL/6 mice with caerulein to induce pancreatitis (Figure 1B). In 
untreated mice, YAP1 and TAZ proteins showed nuclear localization in duct cells of 
the pancreas, with low or absent expression in acinar cells and islet cells20, 30 
(Supplementary Figure 1B). Consistent with the gene set enrichment analysis, the 
YAP1/TAZ target genes Ctgf, Cyr61, Ankrd1 and Amotl2 were overexpressed in 
caerulein-treated animals compared with control PBS-treated mice (Figure 1C). 
Caerulein treatment reduced activatory phosphorylation of the YAP1/TAZ inhibitory 
kinase Lats1 (Figure 1D and Supplementary Figure 2A and B). In line with this, 
we observed increased YAP1 and TAZ protein levels (Figure 1D and 
Supplementary Figure 2A and B), accompanied by strong nuclear localization, 
indicating more active YAP1/TAZ in caerulein-treated animals (Figure 1E). Levels 
of the duct cell marker CK19 were also increased, consistent with acinar-to-duct 
reprogramming (Figure 1D and Supplementary Figure 2A and B). To determine 
the identity of the YAP1/TAZ-responsive cells we performed immunofluorescence 
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co-staining with pancreatic cell type specific markers. Cells co-expressing CK19 and 
the acinar cell marker amylase showed high levels of nuclear YAP1 and TAZ, with 
some stromal cells also positive (Figure 1F). Thus, YAP1/TAZ activity is elevated in 
the injured, inflamed pancreas, particularly in the subset of cells undergoing ADM. 
 
YAP and TAZ are upregulated in ADM lesions induced by KRasG12D 
We next asked whether YAP1/TAZ upregulation is restricted to caerulein-induced 
ADM, or also occurs during ADM induced by oncogenic Ras. The pancreatic tumor 
mouse model LSL-KRasG12D;Pdx1-Cre develops PDAC with long latency and 
displays the whole spectrum of pre-neoplastic lesions31 (Figure 2A). We found a 
strong signal for both YAP1 and TAZ in ADM lesions of these mice, and an 
upregulation of YAP1 and TAZ in pancreatic protein lysates (Figure 2A and B and 
Supplementary Figure 3A and B). Analysis of YAP1 and TAZ immunostaining on 
human pancreatic tissue microarrays showed strong upregulation of YAP1 in human 
ADM and PanIN pre-neoplastic lesions compared with normal acini (Figure 2C-E). 
TAZ was strongly upregulated in ADM and to a lesser extent in PanIN lesions in 
mouse models and human tissues (Figure 2A and C-E). Surprisingly, we found a 
significant downregulation of YAP1 and TAZ protein levels in human PDAC samples 
compared to ADM lesions (Figure 2C-E), suggesting a functional role of YAP1 and 
TAZ particularly during tumor initiation. 
 
YAP1 and TAZ are necessary and sufficient for ADM induction  
To determine the functional requirement for YAP1/TAZ signaling in acinar-to-duct 
reprogramming, we generated conditional floxed alleles of both Yap1 and Taz 
(Supplementary Figure 4A-F). YAP1 and TAZ were efficiently deleted in 
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Yap1fl/fl;Tazfl/fl primary acinar cells (Supplementary Figure 5A and B). We 
combined the floxed Yap1fl/fl and Tazfl/fl alleles with the Cre-inducible oncogenic LSL-
KRasG12D allele, shown to induce ADM in cultured acinar cells14, and assayed ADM 
in vitro (Figure 3A). As expected, Cre-mediated activation of KRasG12D transformed 
acinar cell clusters into tubular duct-like structures (Figure 3B). Deletion of Yap1 
significantly reduced the ability of KRasG12D to induce ADM, but deletion of Taz did 
not. However, in double mutant Yap1/Taz acinar cells, KRasG12D failed to induce 
ADM (Figure 3B and Supplementary Figure 5C and D). 
To address the requirement for YAP1 in vivo, we combined Yap1fl/fl with the Pdx1-
Cre mouse line. Caerulein-induced ADM lesions co-expressing CK19 and amylase 
were readily observed in Yap1fl/fl;Pdx1-Cre mice. However, these lesions were 
positive for YAP1 nuclear staining (Supplementary Figure 6A), suggesting that 
ADM occurred in cells that had escaped Yap1 deletion. Consistent with this, PCR and 
immunoblot analysis showed that the recombination efficiency and consequent 
depletion of YAP1 was incomplete in Yap1fl/fl;Pdx1-Cre mice (Supplementary 
Figure 6B and C). As an alternative model, we used a tamoxifen-inducible Cre line 
under the control of the acinar-specific Ela1 promoter (Ela1-CreERT2) in combination 
with a GFP lineage tracer (R26-LSL-YFP) to allow identification of recombined cells 
(Figure 3C). In this model, GFP-positive acinar cells that had lost both Yap1 and Taz 
were significantly impaired in caerulein-induced ADM formation (Figure 3D), 
supporting a requirement for YAP1 and TAZ in ADM formation in vivo. Importantly, 
co-deletion of Yap1 and Taz did not affect acinar cell viability (Supplementary 
Figure 7A). 
We next examined the effects of ectopic YAP1/TAZ activation in acinar cells by 
generating adenoviral vectors encoding constitutively active phosphorylation mutants 
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of YAP1 (Ad-GFP-YAP1-5SA) and TAZ (Ad-GFP-TAZ-S89A) (Supplementary 
Figure 7B-D). These mutants are predominantly nuclear and able to induce target 
gene expression32, 33: as expected, adenoviral delivery of YAP1-5SA as well as TAZ-
S89A resulted in upregulation of their target genes Ctgf and Cyr61 in primary acinar 
cells (Supplementary Figure 7E). Strikingly, acinar explants infected with either 
Ad-GFP-YAP1-5SA or Ad-GFP-TAZ-S89A, but not Ad-GFP, underwent conversion 
to a duct cell morphology (Figure 3E and F). These data suggest that activation of 
the transcriptional regulators YAP1 and TAZ in acinar cells is sufficient to induce 
ADM.  
 
YAP1/TAZ activation increases expression of JAK-STAT3 pathway components 
To investigate the molecular mechanisms downstream of YAP1/TAZ, we analyzed 
the published transcription profile of cells overexpressing YAP123. Gene set 
enrichment analysis of BIOCARTA-annotated pathways in this dataset34 identified 
the IL6-JAK-STAT3 signaling cascade as strongly regulated by YAP1 overexpression 
(Supplementary Figure 8A). Importantly, JAK-STAT3 signaling was also strongly 
upregulated in mice with pancreatitis (Supplementary Figure 1A), and STAT3 is 
known to be important for oncogenic KRas-induced pancreatic tumor development28, 
29, 35
. To validate the involvement of this pathway downstream of YAP1/TAZ, we 
analyzed the expression of JAK-STAT3 pathway components in the human PDAC 
cell line PANC1, which shows constitutively active YAP1/TAZ (Supplementary 
Figure 8B and C). The receptors LIFR, GP130, IL13RA1 and the transcription factor 
STAT3 were downregulated upon YAP1 and TAZ knockdown in PANC1 cells (Figure 
4A). Accordingly, YAP1/TAZ knockdown reduced STAT3 and LIFR protein levels 
(Figure 4A and Supplementary Figure 8D). Overexpression of constitutively active 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 16
YAP1-5SA or TAZ-S89A led to increased protein levels of STAT3 and LIFR in 
primary mouse acinar cells (Figure 4B and Supplementary Figure 9A and B).  
We next tested whether the JAK-STAT3 pathway genes are direct transcriptional 
targets of the YAP1/TAZ-dependent TEAD transcription factors36. The promoter 
regions of STAT3, LIFR and GP130 contain TEAD4 binding sites, as analyzed by 
genome-wide ENCODE chromatin immunoprecipitation (ChIP) experiments37 
(Supplementary Figure 9C). We confirmed that TEAD4 binding was significantly 
enriched at the promoters of STAT3, LIFR and GP130 by ChIP (Figure 4C). In the 
STAT3 promoter region, one TEAD consensus binding site GT-IIc38 was found 312 
bp to 306 bp upstream of the STAT3 transcription start site (TSS) (Figure 4D). We 
used the entire STAT3 promoter region including this site in a luciferase reporter 
construct transfected into the rat pancreatic acinar cell line AR42J. Overexpression of 
either YAP1-5SA or TAZ-S89A in this cell line significantly increased the luciferase 
activity using the STAT3 promoter construct compared with empty vector control 
(Figure 4D). Mutation of the TEAD binding site abolished the YAP1- and TAZ-
induced luciferase activity (Figure 4D). Deletion of Stat3 did not change the 
expression or protein levels of YAP1 and TAZ in primary acinar cells 
(Supplementary Figure 10A-C). Our results suggest that, through TEAD, YAP1 and 
TAZ regulate the gene expression of the cytokine receptors LIFR and GP130 and the 
transcription factor STAT3. 
 
 
JAK-STAT3 pathway activation in ADM lesions 
To examine whether JAK-STAT3 signaling is involved in ADM, we analyzed STAT3 
activation in response to caerulein-induced pancreatitis. Caerulein treatment led to 
widespread active, phosphorylated STAT3 (pTyr705-STAT3) in the injured pancreas 
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(Figure 4E), in accordance with previous reports29. STAT3 phosphorylation and 
upregulation of STAT3 and LIFR proteins were also detected in caerulein-treated 
pancreas lysates (Figure 4F and Supplementary Figure 10D and E), and Stat3, Lifr, 
Gp130 and Jak1 were upregulated in injured pancreata at the transcriptional level 
(Figure 4F), in agreement with our bioinformatic analysis (Supplementary Figure 
1A). Co-staining with CK19 and amylase revealed increased staining intensity of 
STAT3 and LIFR in KRasG12D-induced ADM cells in the Pdx1-Cre model 
(Supplementary Figure 11A and B).  
 
YAP1/TAZ-dependent extreme ADM sensitization by oncogenic KRasG12D  
The upregulation of the JAK/STAT pathway by YAP1/TAZ predicted an increased 
susceptibility of KRasG12D-mutant acinar cells to inflammation, independently of 
oncogenic transformation. To test this, we challenged control (R26-LSL-YFP;Ela1-
CreERT2) and R26-LSL-YFP;LSL-KRasG12D;Ela1-CreERT2 mice with caerulein to 
induce pancreatitis (Figure 5A). As expected, control mice treated with low doses of 
caerulein showed acinar cell loss, inflammation and a limited number of ADM 
lesions. However, R26-LSL-YFP;LSL-KRasG12D;Ela1-CreERT2 mice displayed a 
dramatic increase in ADM lesions double-positive for amylase and CK19 after 
caerulein treatment, although the recruitment of inflammatory F4/80-positive 
macrophages was similar to caerulein-treated control mice (Figure 5B, C and 
Supplementary Figure 12A). Lineage tracing with the Cre-inducible R26-LSL-YFP 
allele confirmed the acinar cell origin of the ADM lesions (Supplementary Figure 
12B). Thus oncogenic Ras mutations dramatically increase the susceptibility of acinar 
cells to undergo ADM, possibly by increasing acinar cell sensitivity to inflammatory 
cytokines through upregulation of Stat3, Lifr and Gp130.  
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We next tested the significance of YAP1/TAZ and STAT3 in Ras-induced ADM 
sensitization directly. Strikingly, co-deletion of Yap1 and Taz completely blocked the 
enhanced formation of these pancreatitis-induced ADM lesions by KRasG12D (Figure 
5B and C). Pancreata of R26-LSL-YFP;LSL-KRasG12D;Yap1fl/fl;Tazfl/fl;Ela1-CreERT2 
mice showed normal morphology with some signs of caerulein-induced acinar cell 
loss and inflammation similar to the extent observed in control mice (Figure 5B and 
Supplementary Figure 12A). Additionally, in agreement with previous results29, loss 
of STAT3 significantly reduced caerulein-induced CK19-positive ductal structures in 
the mutant KRasG12D background (Figure 5B and C). Ras-induced ADM formation 
resulted in increased expression of the pancreatic progenitor marker Pdx1 and the 
duct marker Sox9, which was dependent on YAP1/TAZ (Figure 5D and 
Supplementary Figure 13A). These results suggest that expression of KRasG12D in 
normal, untransformed acinar cells results in extreme sensitization to pancreatitis-
induced ADM, which is mediated by YAP1/TAZ and STAT3.  
 
JAK-STAT3 pathway acts downstream of YAP1/TAZ in response to oncogenic 
Ras and inflammatory stimuli 
We next addressed the function of YAP1/TAZ and JAK-STAT3 signaling as effectors 
of oncogenic Ras. KRasG12D was activated in adult acinar cells using tamoxifen-
inducible LSL-KRasG12D;Ela1-CreERT2 mice, and gene expression was analyzed 7 days 
later, when pancreas histology was unaltered and no tumor initiation had occurred. 
KRasG12D activation in normal untransformed acinar cells resulted in increased 
expression of the YAP1/TAZ target genes Ctgf and Cyr61, accompanied by 
transcriptional induction of Stat3, Lifr and Gp130 (Figure 6A). Importantly, 
activation of STAT3 pathway genes by oncogenic KRasG12D in this context occurred 
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without caerulein treatment. After deletion of Yap1fl/fl;Tazfl/fl, KRasG12D was unable to 
induce YAP1/TAZ target genes or Stat3, Lifr and Gp130 expression (Figure 6A). 
KRasG12D activation in primary acinar cells in vitro increased YAP1 and TAZ protein 
levels, STAT3 protein levels and STAT3 phosphorylation (Figure 6B and 
Supplementary Figure 13B) but deletion of Yap1fl/fl;Tazfl/fl modestly reduced STAT3 
protein levels and greatly impaired the KRasG12D-induced phosphorylation of STAT3 
in acinar cells in vitro (Figure 6B and Supplementary Figure 13B). In agreement 
with these results, caerulein treatment of tamoxifen-induced LSL-KRasG12D;Ela1-
CreERT2 mice led to a dramatic increase in STAT3 phosphorylation at tyrosine 705 
which was completely abolished in the absence of YAP1 and TAZ (Figure 6C, 
Figure 5D and Supplementary Figure 13A). YAP1 and TAZ deletion also 
diminished the caerulein-induced phosphorylation of STAT3 in pancreatic acinar cells 
wild type for KRas (Supplementary Figure 14A and B). These data indicate that, 
even in the absence of an inflammatory stimulus or tumorigenesis, oncogenic Ras 
mutation leads to YAP1/TAZ and JAK-STAT3 pathway activation, and YAP1 and 
TAZ act upstream of the JAK-STAT3 signaling pathway in oncogenic KRas-induced 
ADM. 
 
Deletion of YAP1 and TAZ reduces inflammation-induced Ras activation 
Inflammatory insults lead to hyperstimulation of oncogenic Ras activity, and 
interfering with the inflammatory signaling cascade interrupts this feedback 
activation18. We next tested whether YAP1/TAZ affects oncogenic Ras activity. 
Caerulein treatment increased Ras activity in mice expressing KRasG12D in acinar cells 
(Supplementary Figure 15A and B) as shown previously18. Deletion of Yap1 and 
Taz in the KRasG12D background reduced Ras activation after caerulein treatment 
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(Supplementary Figure 15A and B). Overexpression of constitutively active YAP1 
in primary acinar cells increased Ras activity (Supplementary Figure 15C). 
Hyperactivating oncogenic Ras by TGFα resulted in a more efficient differentiation 
of acinar to duct cells in vitro39 (Supplementary Figure 16A and B). However, 
YAP1 and TAZ were required for KRasG12D-induced ADM even in the presence of 
TGFα (Supplementary Figure 16A and B). 
 
YAP1 and TAZ are required for KRasG12D-induced PanIN formation  
To determine whether the block to ADM in Yap1fl/fl;Tazfl/fl;LSL-KRasG12D;Ela1-
CreERT2 mice affects the development of pancreatic cancer, we assessed PanIN lesions 
3 months after the transient induction of pancreatitis by caerulein (Figure 7A). At this 
stage, LSL-KRasG12D;Ela1-CreERT2 mice displayed CK19/amylase double-positive 
ADM lesions and CK19- and AB/PAS-positive PanIN lesions (Figure 7B-D). Yap1 
and Taz co-deletion resulted in a striking decrease in ADM lesions and these mice 
were free of PanIN lesions, similar to control mice (Figure 7B-D). These results show 
that acinar cell-specific YAP1/TAZ signaling is essential for oncogenic KRasG12D-
induced PanIN formation in the context of pancreatitis, and that STAT3 signaling 
appears to be a critical downstream factor in this process.  
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Discussion  
Acinar-to-duct reprogramming is now established as an important precursor to PanIN 
lesions and progression to pancreatic cancer, but the molecular mechanisms that drive 
this process have remained unclear. Our results confirm that KRasG12D mutation 
synergizes with inflammatory insults to induce widespread and persistent ADM 
lesions, and we elucidate how this synergy occurs (Figure 7E). We find that the 
transcriptional regulators YAP1 and TAZ are required for KRasG12D to promote 
acinar-to-duct reprogramming, both in vitro and in vivo. In the absence of YAP1 and 
TAZ, KRasG12D is unable to induce PanIN lesions, suggesting that acinar-to-duct 
reprogramming via YAP1/TAZ is an obligate step in pancreatic cancer initiation from 
acinar cells.  
Mechanistically, active YAP1 and TAZ interact with the transcription factor TEAD, 
which binds and upregulates the expression of several genes in the JAK-STAT3 
pathway. This pathway controls the response to inflammatory cytokines like IL-6, 
which is secreted during caerulein-induced pancreatitis and also present at high levels 
in pancreatic tumors, promoting PanIN progression in KRasG12D mice35, 40. A recent 
study found that the IL-6 coreceptor GP130, upregulated by YAP1/TAZ in our study, 
also activates YAP1 independently of STAT341. Additionally, LIFR has been shown 
to act upstream of YAP1 signaling42. This would create a positive feedback loop 
amplifying YAP1 activity. 
Our data in mouse models expressing KRasG12D are consistent with findings in 
cultured cells showing that Ras signaling both stabilizes and activates YAP143, 44. 
Recent studies have implicated YAP1 as an important driver of pancreatic cancer 
progression at later stages in collaboration with oncogenic Ras, and as a mechanism 
of escape from Ras-RAF-MEK-targeted therapies19, 20, 45. However, data from patient 
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samples has shown that the incidence of KRas codon 12 mutations is already over 
90% even in the earliest pre-neoplastic lesions8. Here we show that YAP1 acts 
downstream of oncogenic Ras at this early reprogramming stage. There is likely 
redundancy between YAP1 and TAZ, since co-deletion of Yap1 and Taz is more 
efficient in blocking KRasG12D- induced ADM in the in vitro assay compared to either 
single mutant. YAP1 seems able to compensate for TAZ deletion but not vice versa; 
however, overexpression of constitutively active YAP1 or TAZ alone is sufficient to 
induce ADM. 
We noted that inactivation of YAP1 and TAZ reduced ADM formation more 
efficiently than Stat3 deletion (Figure 5). It has been shown that the Hippo pathway 
also interacts with other signaling pathways that have implications in ADM, such as 
Wnt and Notch pathways23, 46. YAP1/TAZ-dependent regulation of these pathways 
might also contribute to ADM formation. 
The presence of the KRasG12D mutation in ADM cells in an inflammatory 
microenvironment is known to be sufficient for progression to PanIN lesions and 
pancreatic cancer1. Additionally, inflammation in the pancreas creates a feedback 
loop leading to hyperactivation of oncogenic KRasG12D (Figure 7E)18. The KRasG12D 
mutation and subsequent hyperactivation promotes pancreatic cancer at two levels: it 
creates a susceptible “cell of origin” by inducing acinar-to-duct reprogramming; and it 
also acts as the transforming driver that enables progression towards malignancy. This 
model explains why KRas mutations in pancreatic cancer are so common, and why 
they frequently appear very early, as a gatekeeper mutation, in pancreatic acinar cells. 
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Figure legends 
Figure 1. YAP1 and TAZ are upregulated in pancreatitis. 
A. Gene set enrichment analysis of transcription data from caerulein-treated 
pancreata22 identified enrichment of the conserved YAP1 signatures reported by 
Yimlamai23 and Cordenonsi47. Normalized enrichment score (NES) and nominal 
(NOM) P-values are shown. 
B. Scheme showing model of caerulein-induced acute pancreatitis in C57BL/6 mice. 
C. Quantitative RT-PCR of YAP1/TAZ target genes in caerulein-treated versus PBS-
treated pancreata. n = 3 mice each group; means ± SEM are shown; ***P<.005, 
Student’s t-test. 
D. Immunoblots of pancreas lysates from caerulein- and PBS-treated animals. p-
Lats1, phosphorylated Lats1 (Ser909); p-Yap1, phosphorylated Yap1 (Ser112). 
E. Immunohistochemical stains of YAP1 and TAZ in pancreata of caerulein- and 
PBS-treated mice. Scale bars = 50 µm. n = 5-7 mice analyzed. 
F. Triple immunofluorescence of pancreata from caerulein- and PBS-treated animals 
showing the duct marker CK19, the acinar marker amylase and either YAP1 or TAZ. 
Arrowheads indicate ADM cells. Scale bars = 20 µm. n = 5-7 mice analyzed. 
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Figure 2. YAP1 and TAZ are upregulated in ADM lesions induced by KRasG12D.  
A. Immunohistochemical analysis of YAP1 and TAZ in normal (LSL-KRasG12D) 
pancreas and pancreas from 6-month-old LSL-KRasG12D;Pdx1-Cre mice. Scale bars = 
50 µm. Dotted lines highlight mPanIN lesions. n = 4-5 mice analyzed. 
B. Immunoblot analysis of pancreas lysates from control LSL-KRasG12D and LSL-
KRasG12D;Pdx1-Cre mice. p-Lats1, phosphorylated Lats1 (Ser909); p-Yap1, 
phosphorylated Yap1 (Ser112). 
C. Immunohistochemical analysis of YAP1 and TAZ on human pancreatic tissue 
microarrays. Scale bars = 50 µm.  
D and E. Quantification of immunohistochemical staining intensity, ranging from 
absent (0) to highest (6) for YAP1 (D) and TAZ (E) on human pancreatic tissue 
microarrays. n = number of tissue cores. Means ± SD are shown. **P<.01, 
***P<.005, Student’s t-test.   
 
 
 
Figure 3. YAP1 and TAZ are necessary and sufficient for ADM induction. 
A. Scheme showing in vitro assay for KRasG12D-induced ADM. 
B. Brightfield images of pancreatic acinar cell clusters on day 5 after isolation from 
LSL-KRasG12D and LSL-KRasG12D;Yap1fl/fl;Tazfl/fl mice. Cells were infected with 
adenoviruses encoding either GFP (Ad-GFP) or GFP plus Cre (Ad-Cre) on day 0. 
White arrows: tubular ductal structures. Scale bars = 50 µm. Quantification of tubular 
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ductal structures of the indicated genotypes with n = 3-4 mice per group; means ± 
SEM are shown; ***P<.005, n.s. = not significant, Student’s t-test. 
C. Experimental design of caerulein-induced acute pancreatitis in the acinar-specific 
and tamoxifen-inducible Ela1-CreERT2 mouse model combined with the R26-LSL-YFP 
lineage tracer. 
D. Triple immunofluorescence of pancreata from R26-LSL-YFP;Ela1-CreERT2 and 
R26-LSL-YFP;Yap1fl/fl;Tazfl/fl;Ela1-CreERT2 mice treated with caerulein as indicated in 
C. Scale bars = 20 µm. Dotted white lines indicate ADM lesions. Quantification of 
GFP-positive ADM cells (CK19/Amylase double positive) as a percentage of total 
GFP-positive cells in caerulein-treated mice of the indicated genotypes. n = 3 mice 
per group; means ± SEM are shown; **P<.01, Student’s t-test.  
E. Scheme showing in vitro assay for YAP1 and T Z-induced ADM. 
F. Brightfield images (upper panels) and GFP signal (lower panels) of acinar cells 
after 5 days in culture, infected on day 0 with Ad-GFP, Ad-YAP1-5SA-GFP or Ad-
TAZ-S89A-GFP. Scale bars = 25 µm. Quantification of GFP-positive tubular ductal 
structures at day 5, in n = 3 experiments; means ± SEM are shown; ***P<.005, 
Student’s t-test. 
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Figure 4. YAP1/TAZ activation controls JAK-STAT3 signaling via transcription 
of STAT3. 
A. Quantitative RT-PCR of the indicated genes and immunoblots of lysates from 
PANC1 cells expressing shRNAs against YAP1 and TAZ (shYAP/TAZ-#1 and -#2) 
or non-targeted shRNA control (shNT). n = 3; means ± SEM shown. 
B. Immunoblots of primary acinar cell lysates 2 days after isolation and infection with 
Ad-GFP, Ad-YAP1-5SA-GFP or Ad-TAZ-S89A-GFP. 
C. Quantitative ChIP-PCR of the LIFR, GP130 and STAT3 loci (promoter and intron 
regions) using either IgG or an antibody against TEAD4. ZFP37 intron = negative 
control region; CTGF promoter = positive control region. n = 3 experiments; means ± 
SEM shown. 
D. Scheme showing luciferase expression construct with human STAT3 promoter 
region. Base pair (bp) numbers indicate position relative to STAT3 transcription start 
site. Red box indicates GT-IIc TEAD binding motif; genomic sequence of WT GT-IIc 
shown below. Mutant STAT3 promoter construct with a six-base-pair deletion of the 
GT-IIc site (mut GT-IIc) was used as control. Luciferase expression analysis using 
WT and mutant STAT3 promoter regions in AR42J acinar cells one day after 
transfection with empty vector, YAP1-5SA or TAZ-S89A. An artificial TEAD 
luciferase reporter consisting of eight GT-IIc motifs was used as positive control. n = 
3-5 experiments; means ± SEM shown. 
E. Immunohistochemistry showing phosphorylated STAT3 (Tyr705) in pancreata of 
caerulein- and PBS-treated C57BL/6 mice. Scale bars = 50 µm. n = 3 mice analyzed. 
F. Immunoblots of pancreas lysates from PBS- and caerulein-treated animals on day 2 
and day 7 after treatment. p-Stat3, phosphorylated Stat3 (Tyr705). Quantitative RT-
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PCR of JAK-STAT3 pathway genes in caerulein-treated vs. PBS-treated pancreata 2 
days after treatment. n = 3-4 mice per group; means ± SEM shown. *P<.05, **P<.01, 
***P<.005, n.s. = not significant, Student’s t-test. 
 
 
 
Figure 5. YAP1 and TAZ are required for KRasG12D-induced ADM in vivo in 
response to pancreatitis. 
A. Scheme showing experimental design of caerulein-induced acute pancreatitis in 
cooperation with acinar-specific KRasG12D mutation. 
B. H&E stain and amylase and CK19 antibody stains of pancreata from mice of the 
indicated genotypes. Scale bars: H&E (top row) 2 mm; (2nd row) 200 µm; (3rd row) 
50 µm; Amylase 200 µm; CK19 (5th row) 200 µm; (6th row) 50 µm; double 
immunofluorescence 50 µm. 
C. Quantification of CK19+amylase+ ADM pancreatic area in pancreatic sections of 
the genotypes shown in (B). n = 3 mice per genotype; means ± SEM are shown; 
***P<.005, Student’s t-test. 
D. Immunoblots of pancreas lysates from mice of the indicated genotypes treated as 
shown in (A). 
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Figure 6. KRasG12D- and caerulein-mediated activation of STAT3 depends on 
YAP1 and TAZ. 
A. Quantitative RT-PCR of the YAP1/TAZ target genes Ctgf, Cyr61 and Amotl2 and 
the STAT3 pathway genes Stat3, Lifr, and Gp130 in pancreas lysates from Ela1-
CreERT2, LSL-KRasG12D;Ela1-CreERT2 and LSL-KRasG12D;Yap1fl/fl;Tazfl/fl;Ela1-CreERT2 
mice 7 days after the last tamoxifen injection. n = 3-5 mice per genotype; means ± 
SEM are shown; *P<.05; **P<.01; n.s. =  not significant, Student’s t-test. 
B. Immunoblot analysis of primary acinar cells from WT, LSL-KRasG12D and LSL-
KRasG12D;Yap1fl/fl;Tazfl/fl mice, 2 days after isolation and infection with Ad-Cre 
adenovirus. pStat3, phosphorylated Stat3 (Tyr705). 
C. Immunohistochemistry with antibodies against phosphorylated STAT3 (Tyr705) 
and STAT3 in pancreata of the indicated genotypes. Mice were treated with 
tamoxifen and caerulein as indicated in Figure 5A. Scale bars = 50 µm. n = 3-5 mice 
analyzed. 
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Figure 7. YAP1 and TAZ are required for KRasG12D-induced PanIN. 
A. Scheme showing experimental design of caerulein-induced PanIN formation in the 
KRasG12D background. 
B. H&E, amylase and CK19 antibody, and AB/PAS stains of pancreata from mice of 
the indicated genotypes. Scale bars: H&E 200 µm; CK19 200 µm; double 
immunofluorescence 50 µm; AB/PAS (4th row) 200 µm; AB/PAS (5th row) 50 µm.  
C. Quantification of CK19+amylase+ ADM lesions in control, LSL-KRasG12D;Ela1-
CreERT2 and LSL-KRasG12D;Yap1fl/fl;Tazfl/fl;Ela1-CreERT2 mice. n = 3-4 mice per 
genotype; means ± SEM are shown; *P<.05, Student’s t-test. 
D. Quantification of AB/PAS-positive PanIN lesions in control, LSL-KRasG12D;Ela1-
CreERT2 and LSL-KRasG12D;Yap1fl/fl;Tazfl/fl;Ela1-CreERT2 mice. n = 3-4 mice per group; 
means ± SEM are shown; *P<.05, Student’s t-test. 
E. Scheme showing the roles of YAP1 and TAZ in pancreatic cancer initiation by 
inducing ADM in response to oncogenic KRasG12D and inflammation. See text for 
details. 
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Gene signature Normalized enrichment score NOM P-value Reference
YIMLAMAI_YAP_LIVER 3.61486 <.00001
CORDENONSI_YAP_CONSERVED_SIGNATURE 2.77745 <.00001
LABBE_WNT3A_TARGETS_UP 2.68678 <.00001
YAP_ZHAO_MCF10AND3T3 2.61143 <.00001
REACTOME_SIGNALING_BY_WNT 2.46385 <.00001
DANG_MYC_TARGETS_UP 2.46289 <.00001
ALFANO_MYC_TARGETS 2.41509 <.00001
HAN_JNK_SIGNALING_UP 2.36262 <.00001
ABBUD_LIF_SIGNALING_1_UP 2.27401 <.00001
PID_IL6_PATHWAY 2.16067 <.00001
MTOR_UP.V1_UP 2.15835 <.00001
HINATA_NFKB_TARGETS_FIBROBLAST_UP 2.10119 <.00001
DASU_IL6_SIGNALING_UP 1.94122 <.00001
AZARE_STAT3_TARGETS 1.87138 =.00642
PARENT_MTOR_SIGNALING_UP 1.78848 <.00001
DAUER_STAT3_TARGETS_UP 1.73730 <.00001
NGUYEN_NOTCH1_TARGETS_UP 1.61923 =.02371
VILIMAS_NOTCH1_TARGETS_UP 1.60965 =.00873
TGFB_UP.V1_UP 1.39460 =.01903
Supplementary Figure 1. Gene set enrichment analysis of caerulein-treated mice, and YAP1/TAZ localization in untreated pancreas. (A) 
Table of gene sets identified by gene set enrichment analysis of data set generated by Ulmasov et al. 6. Gene signatures significantly enriched 
(nominal (NOM) P-value <.05) are shown and ranked by normalized enrichment score. YAP1 gene signatures are highlighted in red and IL6-STAT3 
pathway signatures are highlighted in green. (B) Immunohistochemical stains with antibodies against YAP1 and TAZ in pancreata of C57BL/6 mice. 
Scale bars (top row) 200 μm; (bottom row) 50 μm. 
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Supplementary Figure 2. (A) Immunoblots of phosphorylated Lats1 (Ser909), Lats1, phosphorylated YAP1 (Ser112), YAP1, TAZ, CK19 and Gapdh 
in pancreas lysates from caerulein- and PBS-treated animals from 3 independent experiments. Numbers under each blot represent band signal 
intensity normalized to Gapdh and relative to samples from PBS-treated animals. (B) Quantification of band signal intensity of immunoblots shown 
in (A); means ± SEM are shown.
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Supplementary Figure 3. (A) Immunoblots of phosphorylated Lats1 (Ser909), phosphorylated YAP1 (Ser112), YAP1, TAZ and Gapdh in pancreas 
lysates from control LSL-KRasG12D and LSL-KRasG12D;Pdx1-Cre mice from 3-4 independent experiments. Numbers under each blot represent 
band signal intensity normalized to Gapdh and relative to samples from control LSL-KRasG12D mice. (B) Quantification of band signal intensity of 
immunoblots shown in (A); means ± SEM are shown. 
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Supplementary Figure 4. Generation of conditional Yap1 and Taz alleles. (A) Gene targeting strategy for conditional deletion of exon 3 in the mouse Yap1 
gene. Red asterisk indicates an induced stop codon by frame shift due to exon 3 deletion. (B) PCR genotyping of mouse embryonic fibroblasts (MEFs) isolated 
from WT or Yap1f/f embryos. Primary Yap1f/f MEFs were infected with either adenovirus-GFP (GFP) or adenovirus-Cre (Cre) and harvested 3 days later. (C) Quanti-
tative RT-PCR analysis (left) and immunoblot analysis (right) of Yap1 in primary Yap1f/f MEFs infected with adenovirus-GFP (GFP) or adenovirus-Cre (Cre) 3 days 
after infection. Immunoblot analysis was performed with antibodies against Yap1 and Gapdh. n = 3 MEF clones isolated from 3 embryos; mean ± SEM is shown; 
**P<.01, Student’s t-test. (D) Gene targeting strategy for conditional deletion of exon 3 in the mouse Taz/Wwtr1 gene. Red asterisk indicates an induced stop codon 
by frame shift due to exon 3 deletion. (E) PCR genotyping of MEFs isolated from WT or Tazf/f embryos 3 days after infection with adenovirus-GFP (GFP) or 
adenovirus-Cre (Cre). (F) Quantitative RT-PCR analysis (left) and immunoblot analysis (right) of Taz in primary Tazf/f MEFs infected with adenovirus-GFP (GFP) or 
adenovirus-Cre (Cre), 3 days after infection. Immunoblot analysis was performed with antibodies against Taz and Gapdh. n = 3 MEF clones isolated from 3 
embryos; mean ± SEM is shown; **P<.01, Student’s t-test.
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Supplementary Figure 5. Deletion efficiency of YAP1 and TAZ in primary acinar cells . (A) Quantitative RT-PCR of Yap1 and Taz in primary acinar cells from 
Yap1fl/fl;Tazfl/fl mice 3 days after isolation and infection with either adenovirus-GFP (Ad-GFP) adenovirus-Cre (Ad-Cre). n = 3 mice per group; mean ± SEM is 
shown; *P<.05; **P<.01; Student’s t-test. (B) Immunoblots of YAP1, TAZ and Actin in pancreas lysates from Yap1fl/fl;Tazfl/fl mice 3 days after isolation and infection 
with either adenovirus-GFP (Ad-GFP) or adenovirus-Cre (Ad-Cre). Numbers under each blot represent band signal intensity normalized to Actin and relative to 
adenovirus-GFP infected cells. Graph shows quantification of band signal intensity of 3 independent experiments; means ± SEM are shown. (C and D) Quantitative 
RT-PCR of Yap1 (A) and Taz (B) in primary acinar cells from LSL-KRasG12D, LSL-KRasG12D;Yap1fl/fl, LSL-KRasG12D;Tazfl/fl and LSL-KRasG12D;Yap1fl/fl;Tazfl/fl mice 
3 days after isolation and infection with adenovirus-Cre. n = 3 mice per group; mean ± SEM is shown; *P<.05; **P<.01; ***P<.005; n.s. = not significant, Student’s 
t-test.
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Supplementary Figure 6. Evaluation of ADM and Yap1 recombination in the Pdx1-Cre model. (A) Triple immunofluorescence of pancreata from control and 
Yap1fl/fl;Pdx1-Cre mice, 4 days after PBS or caerulein treatment, with antibodies against CK19, amylase and YAP1. Scale bars = 20 μm. Arrowheads indicate ADM 
cells. (B) PCR genotyping of tail and pancreas DNA isolated from Yap1f/wt and Yap1f/f;Pdx1-Cre mice. (C) Immunoblot analysis of pancreas lysates from Pdx1-Cre 
and Yap1f/f;Pdx1-Cre mice with Yap1 and Actin antibodies.
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Supplementary Figure 7. TUNEL staining of YAP1/TAZ-deleted pancreas and validation of YAP1/TAZ-expressing adenoviruses. (A) H&E staining, TUNEL 
staining and quantification showing no increase in TUNEL staining in pancreatic sections from Yap1f/f;Tazf/f;Ela1-CreERT2 mice compared with Yap1f/f;Tazf/f mice. 
Inset pictures show examples of TUNEL-positive cells. Scale bars = 200 μm; insets 20 μm. n = 3 mice per group; mean ± SEM is shown; n.s. = not significant, 
Student’s t-test.(B) Schematic diagram of adenovirus constructs produced in the pAd-Track-CMV vector. (C) Immunoblot analysis of Gapdh and Yap1 or Taz in 
primary acinar cells 2 days after isolation and infection with adenovirus-GFP or adenovirus-GFP-YAP1-5SA or adenovirus-GFP-TAZ-S89A. (D) Quantitative 
RT-PCR analysis of Yap1 or Taz in primary acinar cells 2 days after isolation and infection with adenovirus-GFP or adenovirus-GFP-YAP1-5SA or adenovirus-
GFP-TAZ-S89A. n = 3-6 experiments; means ± SEM are shown; ***P<.005, Student’s t-test. (E) Quantitative RT-PCR of the YAP1/TAZ target genes Ctgf and Cyr61 
in primary acinar cells 2 days after isolation. Acinar cells were infected with adenovirus encoding either GFP (Ad-GFP), GFP with YAP1-5SA (Ad-YAP1-5SA) or 
GFP with TAZ-S89A (Ad-TAZ-S89A) on the day of the isolation (day 0). n = 3-6 experiments; means ± SEM are shown; *P<.05; ***P<.005, Student’s t-test.
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Supplementary Figure 8. YAP1/TAZ are active in PANC1 cells and knockdown of YAP1/TAZ results in reduced STAT3 and LIFR protein levels. (A) Gene 
set enrichment analysis of mouse liver organoids overexpressing YAP1 7 identified the BIOCARTA annotated IL6 pathway 27, 28. Normalized enrichment score 
(NES) and nominal (NOM) P-value are shown. (B and C) Immunofluorescence staining of PANC1 cells with Yap1 (B) or Taz (C) antibodies shows nuclear accumu-
lation, indicating constitutive activation of YAP1/TAZ. Scale bars = 20 μm. (D) Immunoblots of STAT3, LIFR, YAP1, TAZ and GAPDH in lysates from PANC1 cells 
expressing shRNAs against YAP1 and TAZ or non-targeted shRNA control (shNT) from 3 independent experiments. Numbers under each blot represent band 
signal intensity normalized to GAPDH and relative to control shNT cells. Graph represents quantification of band signal intensity; means ± SEM are shown.
Gruber Supplementary Figure 8
GAPDH
TAZ
YAP1
LIFR
STAT3
shNT
shYAP1
shTAZ
Experiment 1
(displayed in Fig. 4A)
1.00 0.69
1.00 0.52
1.00 0.36
1.00 0.59
GAPDH
TAZ
YAP1
LIFR
shNT
shYAP1
shTAZ
1.00 0.90
STAT3
shNT
shYAP1
shTAZ
1.00 0.61
GAPDH
TAZ
YAP1
LIFR
STAT3
1.00 0.76
1.00 0.06
1.00 0.98
1.00 0.81
1.00 0.11
1.00 0.87 S
TA
T3
LIF
R
YA
P1 TA
Z
0.0
0.2
0.4
0.6
0.8
1.0
1.2
1.4
R
el
at
iv
e 
si
gn
al
 in
te
ns
ity
[n
or
m
al
iz
ed
 to
 G
ap
dh
] shNTshYAP1/shTAZ
Experiment 2 Experiment 3
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPTA
STAT3
GP130
LIFR
TSS -456 bp / -298 bp
TSS -336 bp / -178 bp
TSS -288 bp / -182 bp
C
Supplementary Figure 9. Overexpression of active YAP1 and TAZ leads to increased STAT3 and LIFR protein levels and ENCODE dataset indicates peak 
for TEAD4 binding at the STAT3, LIFR and GP130 promoters. (A and B). Immunoblots of primary acinar cell lysates 2 days after isolation and infection with 
Ad-GFP, Ad-YAP1-5SA-GFP (A) or Ad-TAZ-S89A-GFP (B) from 3 independent experiments. Numbers under each blot represent band signal intensity normalized 
to Gapdh and relative to control Ad-GFP infected cells. Graphs represent quantification of band signal intensity; means ± SEM are shown. (C) USCS Genome 
Browser view of TEAD4 ChIP-seq tracks from the ENCODE data set for human H1-hES cells. STAT3, GP130 and LIFR loci are shown. PCR amplicons used for 
quantitative ChIP assay are indicated in red with their positions relative to transcription start sites (TSS).
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Supplementary Figure 10. STAT3 deletion in acinar cells has no effect on YAP1 and TAZ expression and protein levels and STAT3 is activated in 
response to caerulein treatment. (A) Quantitative RT-PCR of Stat3, Yap1 and Taz in primary acinar cells from Stat3f/f mice 3 days after isolation and 
infection with either adenovirus-GFP (Ad-GFP) adenovirus-Cre (Ad-Cre). n = 3 mice per group; mean ± SEM is shown; **P<.01; Student’s t-test. (B) 
Immunoblots of Stat3, YAP1, TAZ and Gapdh in pancreas lysates from Stat3f/f mice 3 days after isolation and infection with either adenovirus-GFP (GFP) 
or adenovirus-Cre (Cre). Numbers under each blot represent band signal intensity normalized to Gapdh and relative to adenovirus-GFP infected cells. (C) 
Quantification of band signal intensity of 3 independent experiments shown in (B); means ± SEM are shown. (D) Immunoblots of Lifr, phosphorylated Stat3 
(Tyr705), Stat3, YAP1, TAZ and Gapdh in pancreas lysates from PBS- and caerulein-treated animals on day 2 (d2) and day 7 (d7) after treatment from 3 
independent experiments. Numbers under each blot represent band signal intensity normalized to Gapdh and relative to samples from PBS-treated animals. 
(E) Quantification of band signal intensity of immunoblots shown in (D); means ± SEM are shown.  
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Supplementary Figure 11. STAT3 and LIFR are upregulated in ADM lesions. (A and B) Triple immunofluorescence of pancreata from LSL-KRasG12D and 
LSL-KRasG12D;Pdx1-Cre mice with antibodies against the duct marker CK19, the acinar marker amylase and either STAT3 (A) or LIFR (B). Arrowheads 
indicate ADM cells. Scale bars = 20 μm. 
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Supplementary Figure 12. Inflammation and lineage tracing in caerulein-treated pancreata. (A and B) Immunohistochemistry with 
antibodies against the macrophage marker F4/80 (A) or GFP (B) in pancreata from R26-LSL-YFP;Ela1-CreERT2, R26-LSL-YFP;LSL-
KRasG12D;Ela1-CreERT2, and R26-LSL-YFP;LSL-KRasG12D;Yap1fl/fl;Tazfl/fl;Ela1-CreERT2 mice. Mice were injected 5 times with tamoxifen and 
treated with caerulein one week later as indicated in Figure 5A. Inset pictures show examples of F4/80-positive cells (A) and GFP-positive 
cells (B) at higher magnification. Scale bars = 200 μm; insets 20 μm.
Gruber Supplementary Figure 12
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Supplementary Figure 13. (A) Immunoblots and quantification of band signal intensities of phosphorylated Lats1 (Ser909), Lats1, phosphorylated Stat3 (Tyr705), 
Stat3, Pdx1, Sox9 and Gapdh in pancreas lysates from caerulein-treated R26-LSL-YFP;Ela1-CreERT2, R26-LSL-YFP;LSL-KRasG12D;Ela1-CreERT2, and R26-LSL-
YFP;LSL-KRasG12D;Yap1f/f;Tazf/f;Ela1-CreERT2 mice. Mice were injected 5 times with tamoxifen and treated with caerulein one week later as indicated in Figure 5A. 
Numbers under each blot represent band signal intensity normalized to Gapdh and relative to R26-LSL-YFP;Ela1-CreERT2 mice; means ± SEM are shown. (B) 
Immunoblots and quantification of band signal intensity of immunoblots from WT, LSL-KRasG12D and LSL-KRasG12D;Yap1f/f;Tazf/f primary acinar lysates 2 days after 
isolation and adenovirus-Cre infection. Immunoblots of phosphorylated Stat3 (Tyr705), Stat3, Yap1, Taz and Actin are shown. Numbers under each blot represent 
band signal intensity normalized to Actin and relative to WT cells; means ± SEM are shown.
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Supplementary Figure 14. Caerulein-mediated activation of STAT3 depends on YAP1 and TAZ. (A) Scheme showing experimental design of 
caerulein-induced acute pancreatitis in the acinar-specific and tamoxifen-inducible Ela1-CreERT2 mouse model combined with the R26-LSL-YFP 
lineage tracer. (B) Double immunofluorescence of pancreata from R26-LSL-YFP;Ela1-CreERT2  and Yap1f/f;Tazf/f;R26-LSL-YFP;Ela1-CreERT2 
mice with antibodies against GFP, labeling recombined cells, and phosphorylated Stat3 (Tyr705). Mice were treated with tamoxifen and with either 
PBS or caerulein as indicated in (A). Scale bars = 50 μm.
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Supplementary Figure 15. Deletion of YAP1 and TAZ reduced the caerulein-induced increase in Ras activity. (A) Scheme showing experimental design of 
caerulein-induced acute pancreatitis in cooperation with acinar-specific tamoxifen-inducible KRasG12D mutation. (B) Immunoblots (IB) of pancreas lysates from  
LSL-KRasG12D;Ela1-CreERT2  and Yap1f/f;Tazf/f;LSL-KRasG12D;Ela1-CreERT2  mice treated with tamoxifen and either PBS or caerulein as indicated in (A). Antibodies 
against Ras, phosphorylated p-Erk1/2 (Thr202/Tyr204), Erk1/2 and Gapdh were used. Ras-GTP levels were determined with an active Ras pull-down assay using the 
Ras-binding-domain from Raf fused to GST (Raf-RBD-GST). Representative immunoblots are shown and graphs show quantification of band signal intensity of 
Ras-GTP normalized to Gapdh and relative to control PBS-treated LSL-KRasG12D;Ela1-CreERT2 mice (left graph) and band signal intensity of phosphorylated p-Erk1/2 
(Thr202/Tyr204) normalized to Gapdh and relative to control PBS-treated mice (right graph) from 3-4 independent experiments; means ± SEM are shown. (C) Immunob-
lots (IB) of primary acinar cells from LSL-KRasG12D mice, 3 days after isolation and infection with adenovirus-Cre together with either adenovirus-GFP (GFP) or 
adenovirus-YAP1-5SA (YAP1-5SA), with antibodies against Ras, phosphorylated p-Erk1/2 (Thr202/Tyr204), Erk1/2 and Gapdh. Ras-GTP levels were determined with 
an active Ras pull-down assay using the Ras-binding-domain from Raf fused to GST (Raf-RBD-GST). Asterisks indicate non-specific bands.
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Supplementary Figure 16. YAP1 and TAZ are required for ADM after TGFα-induced increase in oncogenic Ras activity. (A) Immunoblots (IB) of 
primary acinar cells from WT, LSL-KRasG12D and LSL-KRasG12D;Yap1f/f;Tazf/f mice 3 days after isolation and adenovirus-Cre infection with antibodies 
against Ras, phosphorylated p-Erk1/2 (Thr202/Tyr204), Erk1/2 and Gapdh. Ras-GTP levels were determined with an active Ras pull-down assay using the 
Ras-binding-domain from Raf fused to GST (Raf-RBD-GST). Cells were either untreated or treated with TGFα (50 ng/ml) for 3 days. Asterisks indicate 
non-specific bands. Representative immunoblots are shown and graphs show quantification of band signal intensity from 3 independent experiments. Band 
signal intensities of Ras-GTP (left graph) or phosphorylated p-Erk1/2 (right graph) were normalized to Gapdh and are shown as relative to LSL-KRasG12D 
mice without TGFα treatment; means ± SEM are shown. (B) Brightfield images of pancreatic acinar cell clusters on day 5 after isolation from WT, 
LSL-KRasG12D and LSL-KRasG12D;Yap1f/f;Tazf/f mice. Cells were infected with adenovirus-Cre on day 0 and either untreated or treated with TGFα (50 ng/ml) 
from day 0 for 5 days. Scale bars = 100 μm. Graph shows quantification of tubular ductal structures of the indicated genotypes with n = 3 mice per group; 
means ± SEM are shown; ***P<.005, *P<.05, Student’s t-test.
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Supplementary Table 1. List of primers for quantitative RT-PCR 
 
Species Gene Primer Sequence 
Human GAPDH forward 5'-AGCCACATCGCTCAGACAC-3' 
  
 
reverse 5'-GCCCAATACGACCAAATCC-3' 
        
Human YAP1 forward 5'-CCCAGATGAACGTCACAGC-3' 
  
 
reverse 5'-GATTCTCTGGTTCATGGCTGA-3' 
        
Human TAZ forward 5'-ATCCCAGCCAAATCTCGTGA-3' 
  
 
reverse 5'-GCCCTGCGGGTGGGT-3' 
        
Human ANKRD1 forward 5'-AACGGAAAAGCGAGAAACTG-3' 
  
 
reverse 5'-TTCAAGCTTTGATCTTTGTTCTAGTT-3' 
        
Human AMOTL2 forward 5'-AGGCTGCAGAGAGACAATGAG-3' 
  
 
reverse 5'-CTCAGAGAGCCGCTGGATT-3' 
        
Human STAT3 forward 5'-CCCTTGGATTGAGAGTCAAGA-3' 
  
 
reverse 5'-AAGCGGCTATACTGCTGGTC-3' 
        
Human LIR forward 5'-GAGTATGTATGTGGTGACAAAGGAA-3' 
  
 
reverse 5'-TCACCACTCCAACAATGACAG-3' 
        
Human GP130 forward 5'-AGGACCAAAGATGCCTCAAC-3' 
  
 
reverse 5'-GAATGAAGATCGGGTGGATG-3' 
        
Human IL13RA1 forward 5'-GTGCCTTTAACTTCCCGTGT-3' 
  
 
reverse 5'-CCCATTGCACATATAGGTCATC-3' 
        
Human JAK1 forward 5'-CTGGAGTATCTGTTTGCTCAGG-3' 
  
 
reverse 5'-GCTCGGTCTTGGGGTCTC-3' 
        
Mouse Gapdh forward 5'-TGTCCGTCGTGGATCTGAC-3' 
  
 
reverse 5'-CCTGCTTCACCACCTTCTTG-3' 
        
Mouse Yap1 forward 5'-GTCCTCCTTTGAGATCCCTGA-3' 
  
 
reverse 5'-TGTTGTTGTCTGATCGTTGTGAT-3' 
        
Mouse Taz forward 5'-TGCTACAGTGTCCCCACAAC-3' 
  
 
reverse 5'-TGACCGGAATTTTCACCTGT-3' 
        
Mouse Ctgf forward 5'-GTGCCAGAACGCACACTG-3' 
  
 
reverse 5'-CCCCGGTTACACTCCAAA-3' 
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Mouse Cyr61 forward 5'-GGATCTGTGAAGTGCGTCC-3' 
  
 
reverse 5'-CTGCATTTCTTGCCCTTTTT-3' 
        
Mouse Ankrd1 forward 5'-AACGGAAAAGCGAGAAACTG-3' 
  
 
reverse 5'-TTCAAGCTTTGATCTTTGTTCTAGTT-3' 
        
Mouse Amotl2 forward 5'-TGACTGTACCTAAGCCGAACC-3' 
  
 
reverse 5'-GCACACACCTGCCTAGACAAT-3' 
        
Mouse Stat3 forward 5'-GTTCCTGGCACCTTGGATT-3' 
  
 
reverse 5'-CAACGTGGCATGTGACTCTT-3' 
        
Mouse Lifr forward 5'-TGTTTGTGGTGACCAAGGAA-3' 
  
 
reverse 5'-TTACCACGCCAACAATGACA-3' 
        
Mouse Gp130 forward 5'-GACCCGATAGAAGGAACATGAC-3' 
  
 
reverse 5'-TGGTGCTGACATCTTGCAG-3' 
  
  
  
Mouse Jak1 forward 5'-GGAGTACTACACAGTCAAGGACGA-3' 
  
 
reverse 5'-AAACATTCCGGAGCGTACC-3' 
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Supplementary Table 2. List of primers for quantitative ChIP analysis 
 
Species Gene Primer Sequence 
Human ZFP37 forward 5'- ACCATGCCCAGCTACGTTTTGT -3' 
  intron reverse 5'- AGGATTGCTTGAGCTCAGGAGT -3' 
        
Human CTGF forward 5'- TTCAGACGGAGGAATGCTGAGTGT -3' 
  promoter reverse 5'- CCAATGAGCTGAATGGAGTCCTAC -3' 
        
Human STAT3 forward 5'- TCACGCACTGCCAGGAACTCA -3' 
  promoter reverse 5'- GTGCTGGCTGTTCCGACAGTT -3' 
        
Human STAT3 forward 5'- AGTGCTGGGATTACAGGCATGA -3' 
  intron reverse 5'- GTTTGTGTTGGGGATAGCCCATGA -3' 
        
Human LIFR forward 5'- GAAGGTTAGATTGGCCCCATGGAT -3' 
  promoter reverse 5'- AAGCTTTTGCCTCCAGGCCA -3' 
        
Human LIFR forward 5'- TTGCAGGACTTCTGAGAGCCTT -3' 
  intron reverse 5'- GAGGGGAGTCTATGTATGGTCAGT -3' 
        
Human GP130 forward 5'- GCTCCAGTTCATGACCCCGTTATT -3' 
  promoter reverse 5'- ATTCCCGTAACGCGGCTCTT -3' 
        
Human GP130 forward 5'- GTGAAAGGCTTCAGAAACACTTG -3' 
  intron reverse 5'- AGATACACTAGATAGCCGCAAAG -3' 
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Supplementary Materials and Methods 
 
Mouse Lines 
For genotyping of the Yap1 and Taz conditional alleles, genomic DNA from ear snips, 
cells or tissues was used with PCR primers for Yap1: Yap1-f 5’-
GCTTCCTGTAGTCATGTGGTTGT-3’, Yap1-r 5’-
TGTTGTCATATGCCATTGTGTAA-3’ and Yap1-delta-f 5’-
CACAGAGATCCTCCTGTCTCAG-3’ producing PCR bands of 138 bp (wildtype), 
154 bp (floxed) and 457 bp (deleted). PCR primers used for Taz/Wwtr1 genotyping 
were Taz-f 5’-AGCAAAGTAAGGGCACTGTATG-3’, Taz-r 5’-	
GCTCCCAAACCACATCACAG-3’ and Taz-delta-r 5’-
TCTACTCTTGGCTCTTAGCTGG-3’ producing PCR bands of 161 bp (wildtype), 
295 bp (floxed) and 249 bp (deleted). See diagrams in Supplementary Fig 4A and D 
for allele details and Supplementary Fig 4B,C and 4E,F for validation of the knock-
out alleles in Yap1fl/fl and Tazfl/fl primary MEFs isolated from E13.5 embryos. 
Previously described mouse lines used were Stat3fl/fl 1, Pdx1-Cre 2, R26-LSL-YFP 3, 
LSL-KRasG12D 4 and Ela1-CreERT2 5.  
These lines were intercrossed to obtain the different genotypes. In order to maintain a 
similar genetic background in the knock-out and control groups, mice carrying the 
R26-LSL-YFP, LSL-KRasG12D and Ela1-CreERT2 alleles were first crossed into the 
Yap1fl/fl;Tazfl/fl or the Stat3fl/fl background. The resulting mice carrying the Yap1fl/+ and 
Tazfl/+ or the Stat3fl/+ alleles together with the R26-LSL-YFP, LSL-KRasG12D and Ela1-
CreERT2 alleles were then intercrossed to breed out the floxed alleles (control groups) 
or to obtain the homozygous floxed alleles (knock-out groups). Controls for the LSL-
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KRasG12D;Pdx1-Cre mice were litter mates harbouring the LSL-KRasG12D allele 
without the Pdx1-Cre transgene. 
All mouse experiments were performed on sex- and age-matched adult mice at the 
age of 8-14 weeks and analysed at the indicated time points. The LSL-
KRasG12D;Pdx1-Cre and respective control mice were analysed at 6 months.  
For the induction of recombination in pancreatic acinar cells using the Ela1-CreERT2 
mouse line, adult mice (8-14 weeks) were injected intra-peritoneally with 100 µg/g 
body weight tamoxifen (Sigma-Aldrich) dissolved in peanut oil (Sigma-Aldrich) once 
daily for five consecutive days. 
 
Cell lines 
The pancreatic adenocarcinoma cell line PANC-1 and the rat acinar cell line AR42J 
were purchased from HPA Cultures and authenticated by Short Tandem Repeat (STR) 
profiling (Promega). PANC-1 cells were cultured in DMEM medium (Life 
technologies) containing 10 % fetal bovine serum (FBS) and Penicillin/Streptomycin 
(Sigma-Aldrich) and AR42J cells were cultured in RPMI medium (Life technologies) 
supplemented with 10 % FBS and Penicillin/Streptomycin (Sigma-Aldrich). All cell 
lines were passaged for a maximum of 6 months after authentication. 
 
Immunofluorescence and immunohistochemistry staining 
Mice were euthanized by cervical dislocation and the pancreas was dissected out and 
fixed overnight in 10 % neutral buffered formalin, then washed with 70 % ethanol, 
processed and embedded into paraffin. Sections were cut at a thickness of 4 µm and 
deparaffinized in Histo-Clear (National Diagnostics), rinsed in ethanol and washed in 
water and PBS. Sections were stained with Haematoxylin & Eosin (H&E) or with 
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antibodies for immunofluorescence or immunohistochemistry. Antigen retrieval was 
performed by incubating sections in 10 mM sodium citrate (pH 6) for 10 minutes at 
sub-boiling temperature and keeping them in the same buffer for 30 min before 
washing with PBS.  
For immunohistochemistry, endogenous peroxidase was blocked with 3 % hydrogen 
peroxide for 5 min followed by washes with PBS. Epitope blocking was performed 
for 1 h at room temperature (RT) with blocking solution: 1 % bovine serum albumin 
(Sigma-Aldrich), 5 % normal donkey serum (Millipore) and 0.4 % Triton X-100 
(Sigma-Aldrich) diluted in PBS. Sections were then incubated overnight at 4 ºC with 
primary antibodies diluted in blocking solution. Next day, sections were washed with 
PBS and incubated for 2 h at RT with secondary antibodies (Life Technologies) 
diluted in blocking solution, then washed again and staining was visualized with 3.3’-
diaminobenzidine (DAB) followed by counterstaining with Mayer’s hematoxylin. The 
sections were then dehydrated and mounted. 
For immunofluorescence, epitope blocking, antibody and washing steps were 
performed as above except the secondary antibody solution contained DAPI at a 
concentration of 0.75 nM, and sections were stained with 0.1 % Sudan Black B 
(Sigma-Aldrich) diluted in 70 % ethanol for 30 min before washing and mounting. 
Antibodies used were YAP1 (Cell Signaling; #4912 and #14074), TAZ (Sigma-
Aldrich; HPA007415), CK19 (DHSB; TROMA-III), Amylase (Santa Cruz; sc-12821 
and Sigma-Aldrich; A8273), GFP (Abcam; ab6673), STAT3 (Cell Signaling; #4904), 
p-STAT3 (Tyr705; Cell Signaling; #9131), LIFR (Santa Cruz; sc-659) and F4/80 
(eBiosciences; #14-4801). 
Confocal images were acquired on Zeiss 710, 780 or 880 confocal microscopes and 
processed using Zeiss AxioVision or Zeiss ZEN software. For quantifications, images 
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of the whole pancreatic area of three different levels for each mouse were acquired on 
the Zeiss Axio Scan.Z1 slide scanner, processed and quantified using the Zeiss ZEN 
software. 
TUNEL assay was performed on paraffin-embedded sections using the DeadEnd 
Colorimetric TUNEL system (Promega) according to manufacturer’s protocol. 
Immunofluorescence staining in PANC1 cells was performed on glass coverslips. 
Cells were grown on glass coverslips and fixed for 10 min on ice with 4 % 
paraformaldehyde. After washing, cells were blocked in blocking solution for 1 h at 
RT and then incubated overnight at 4 ºC with YAP1 (Cell Signaling; #4912) or TAZ 
(Sigma-Aldrich; HPA007415) antibodies diluted in blocking solution. Cells were then 
washed and incubated for 2 h at RT with secondary antibodies (Life Technologies) 
diluted in blocking solution containing 0.75 nM DAPI. After three washes with PBS, 
cells were mounted and confocal images were obtained with a Zeiss 710 confocal 
microscope. 
 
Gene set enrichment analysis 
Gene set enrichment analysis was performed on the published transcription profile of 
C57BL/6 Jackson mice treated with caerulein or PBS 6 and on the transcription profile 
of mouse liver organoids overexpressing YAP1 7. The settings in all analyses were: 
number of permutations = 1000, permutation type = gene set, enrichment statistics = 
weighted, metric for ranking genes = t-test. The identified gene sets (nominal p-value 
P<.05) were rank-ordered by normalized enrichment score (NES). Published gene 
signatures used were: YIMLAMAI_YAP_LIVER 7, 
CORDENONSI_YAP_CONSERVED_SIGNATURE 8, 
LABBE_WNT3A_TARGETS_UP 9, YAP_ZHAO_MCF10AND3T3 10, 
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REACTOME_SIGNALING_BY_WNT 11, 12, DANG_MYC_TARGETS_UP 13, 
ALFANO_MYC_TARGETS 14, HAN_JNK_SIGNALING_UP 15, 
ABBUD_LIF_SIGNALING_1_UP 16, PID_IL6_PATHWAY 17, MTOR_UP.V1_UP 
18, HINATA_NFKB_TARGETS_FIBROBLASTS_UP 19, 
DASU_IL6_SIGNALING_UP 20, AZARE_STAT3_TARGETS 21, 
PARENT_MTOR_SIGNALING_UP 22, DAUER_STAT3_TARGETS_UP 23, 
NGUYEN_NOTCH1_TARGETS_UP 24, VILIMAS_NOTCH1_TARGETS_UP 25, 
TGFB_UP.V1_UP 26 and BIOCARTA_IL6_PATHWAY 27, 28. 
 
shRNA knockdown 
Human PANC1 cells stably expressing non-targeting shRNA (shNT) or two 
independent shRNAs against YAP1 and TAZ (shYAP1/TAZ-#1 and -#2) were 
generated using lentiviral-based vectors pLL3.7-GFP (Addgene #11795) for shRNA 
against YAP1 and tetracycline-inducible pLKO-Tet-On-PURO (Addgene #21915) for 
shRNA against TAZ and selected for GFP signal and puromycin resistance. shRNA 
sequences were:  
shTAZ-#1: 5’-GCCCTTTCTAACCTGGCTGTACTCGAGTACAGCCAGGTTA 
GAAAGGGCTTTTTG-3’;  
shTAZ-#2: 5’-CAGCCAAATCTCGTGATGAATCTCGAGATTCATCACGAGA 
TTTGGCTGTTTTTG-3’;  
shYAP1-#1: 5’-CCCAGTTAAATGTTCACCAATCTCGAGATTGGTGAACA 
TTTAACTGGGTTTTTG-3’;  
shYAP1-#2: 5’-CAGGTGATACTATCAACCAAACTCGAGTTTGGTTGA 
TAGTATCACCTGTTTTTG-3’.  
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Quantitative RT-PCR 
RNA was isolated from dissected pancreata using Qiagen Micro-RNA kit (Qiagen) or 
from primary acinar cells using the Qiagen Mini-RNA kit (Qiagen) or the MagMAX 
Total RNA isolation kit (Life Technologies). The cDNA was generated using the 
Transcriptor First Strand cDNA synthesis kit (Roche Diagnostics) and was used for 
qPCR SYBR-green (Life Technologies) detection using the primers listed in 
Supplementary Table 1. 
 
Human Pancreatic Tissue Array 
Human YAP1 and TAZ protein levels were examined on the human pancreatic tissue 
arrays BIC14011 and PA207, consisting of pancreatitis, PanIN and PDAC, purchased 
from US Biomax, Inc. Cores were stained with YAP1 (Cell Signaling; #4912) and 
TAZ (Sigma-Aldrich; HPA007415) antibodies as described in Immunofluorescence 
and immunohistochemistry staining. The staining intensity was then scored on a 
scale ranging from 0 (absent) to 6 (strong positive signal). 
 
Chromatin Immunoprecipiation 
Chromatin Immunoprecipitation (ChIP) using PANC1 cells with a TEAD4 antibody 
(Abcam; ab58310) was performed as described 29. The recovery of DNA was 
determined by quantitative RT-PCR with SYBR-green (Life Technologies). Primers 
for quantitative ChIP analysis are listed in Supplementary Table 2. 
 
Luciferase expression assay 
Luciferase assays were performed in rat acinar AR42J cells with the LightSwitch 
Luciferase Assay System (Active Motif). The luciferase reporters used were 
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pLightSwitch-STAT3-PROM-722049 (Active Motif) containing 1393 bp of the 
human STAT3 promoter (STAT3 WT), and the same vector where the TEAD binding 
motif (GT-IIc) 238 bp to 233 bp upstream of the TSS was deleted by site directed 
mutagenesis (STAT3 mut GT-IIc). For the positive control, 8xGT-IIc motifs from the 
YAP/TAZ/TEAD-responsive reporter pGL3b-8xGT-IIc (Addgene #34615) were 
subcloned into the pLightSwitch empty promoter vector (Active Motif). Cells were 
co-transfected with pcDNA3 empty vector or the vectors encoding the YAP1 and 
TAZ phosphorylation mutants pcDNA3-HA-YAP1-5SA and pCS2-FLAG-TAZ-
S89A (kind gifts from S. Piccolo). Cells were co-transfected with the pGL3-Control 
Vector (Promega) to normalize for transfection efficiency. 
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